Pharmigene

Pharmigene Book Value per Share

The Book Value per Share of Pharmigene (7595.TWO) as of Oct 16, 2026 is 5.52 TWD. In the previous year, Book Value per Share was 6.92 TWD — a change of -20.23% (lower).

Book Value per Share

5.52TWD

YoY

-20.23%

Last updated:

Book Value per Share of Pharmigene is 2025 5.52 TWD. Book Value per Share of Pharmigene was 2024 6.92 TWD. It decreases by -20.23% lower compared to the previous year.

The Pharmigene Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2018
3.29 TWD
Jan 1, 2019
2.59 TWD
Jan 1, 2020
8.11 TWD
Jan 1, 2021
7.57 TWD
Jan 1, 2022
6.73 TWD
Jan 1, 2023
8.80 TWD
Jan 1, 2024
6.92 TWD
Jan 1, 2025
5.52 TWD
The Pharmigene Book Value per Share history
YEARBook Value per ShareYoY
5.52TWD-20.23%
6.92TWD-21.40%
8.80TWD+30.71%
6.73TWD-11.11%
7.57TWD-6.68%
8.11TWD+213.24%
2.59TWD-21.15%
3.29TWD-7.49%
3.55TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Pharmigene Stock analysis

What does Pharmigene do? Pharmigene Inc, listed on the Taiwan Stock Exchange under ticker 7595.TWO with ISIN TW0007595B13, is a biotechnology company headquartered in Taipei City, Taiwan. The company went public on December 22, 2020. Pharmigene focuses on the development and commercialization of pharmaceutical genetic diagnostic products, operating within the healthcare sector. Its primary activities involve genomics science, specifically creating diagnostic kits, testing technologies, and comprehensive solutions for drug genomics research and development in precision medicine. The company offers a range of molecular diagnostic products, including the AutoEx16 automatic nucleic acid extractor, various gene test kits such as the Clopidogrel drug effectiveness test for CYP2C19*2&*3, and several test suites like SGE 1502, SGE 3101, and SGE 5701. Additionally, Pharmigene provides testing services encompassing drug genetic testing, functional medical testing, and personalized genetic testing. The firm primarily serves the Taiwan market, with some presence in other regions. Pharmigene's website is https://pharmigene.com.tw/. The company's operations are centered on advancing precision medicine through innovative diagnostic tools and services, aiming to support healthcare providers and researchers in tailoring medical treatments based on genetic profiles. Pharmigene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pharmigene stock

Book Value per Share of Pharmigene is 5.52 TWD in 2025.

Book Value per Share of Pharmigene changed from 6.92 TWD to 5.52 TWD, representing a -20.23% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share Pharmigene since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Pharmigene

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Pharmigene